HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target on the stock.

November 13, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating and $22 price target for Esperion Therapeutics (NASDAQ:ESPR), potentially influencing investor confidence and stock performance.
The reiteration of a Buy rating and maintenance of a $22 price target by a reputable analyst could lead to increased investor confidence and a positive short term impact on ESPR's stock price. Analyst ratings are known to influence market perceptions and can result in price movements, especially when they come from established financial institutions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100